News
2011/12/6: Largest clinical trial of point-of-care DNA testing begins in Italy
“Spartan Bioscience today announced the start of GENE-MATRIX—the largest clinical trial to date of point-of-care DNA testing in medicine. The randomized prospective trial will enroll 4,000 patients over 2 years at up to 40 hospitals in Italy.”
2011/11/3: First clinical trial of point-of-care DNA testing in medicine enables cardiac stent patients to receive personalized antiplatelet therapy
“Spartan Bioscience today announced data from the RAPID GENE study showing that point-of-care DNA testing successfully identified patients carrying the CYP2C19*2 gene at the time of cardiac catheterization. Cardiologists were then able to prescribe antiplatelet therapy according to the patient’s genotype. This personalized medicine approach completely eliminated high on-treatment platelet reactivity (HPR) in CYP2C19*2 carriers.”
2011/5/30: Ontario leads clean water research and innovation
“Spartan Bioscience will develop a rapid, on-site water testing system that will reduce analysis times from 72 hours to 2-4 hours, with significant commercial and environmental applications…Ontario is providing over $2.7M to support Spartan Bioscience, as part of a $7.8M project.”
2011/1/10: Spartan Bioscience announces Alere as exclusive distributor for Germany, Austria and Switzerland
“Spartan Bioscience today announces an exclusive distribution agreement with Alere GmbH for distribution of the Spartan RX CYP2C19 in Germany, Austria and Switzerland…Alere will concentrate its efforts on reaching customers in surgery suites and catheterization labs within hospitals and other medical centers.”
2010/12/20: Spartan Bioscience announces CE Marking for first point-of-care DNA personalized medicine testing system
“Spartan Bioscience today announced its Spartan RX CYP2C19 received a CE IVD Mark under the European Directive on In Vitro Diagnostic Medical Devices. The CE Mark certification allows commercial distribution in Europe as well as in all countries recognizing the CE Mark in the Middle East, Africa, Latin America, and Asia-Pacific regions.”
2010/8/10: Spartan Bioscience announces first point-of-care DNA testing system for personalized medicine
“Spartan Bioscience today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine.”
